BioScrip, Inc. (BIOS) Misses Q1 EPS by 10c; Guides FY14 Revs Above Consensus

BioScrip, Inc. (NASDAQ: BIOS) reported Q1 EPS of ($0.13), $0.10 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $239.6 million versus the consensus estimate of $222.65 million.

BioScrip, Inc. sees FY2014 revenue of $940-980 million, versus the consensus of $919.94 million.

For earnings history and earnings-related data on BioScrip, Inc. (BIOS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Vivos Therapeutics posts 35% revenue gain but widens net loss
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c